drugset / Trial / NCT04539223
A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy
Phase 4
Unknown
60 enrolled
Canadian Medical and Surgical Knowledge Translation Research Group
Amgen · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a multicenter, randomized, open label study with blinded outcome assessment to evaluate the impact of additional/intensive LDL-cholesterol reduction with evolocumab on carotid artery atherosclerotic plaques in higher risk subjects with severe asymptomatic but vulnerable plaques.
Timeline
- Start
- 2020-08-28
- Primary completion
- 2022-04
- Completion
- 2022-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Evolocumab | Monoclonal antibody | 140 mg | Subcutaneous |